425: Waters Corporation and BD's Biosciences & Diagnostic Solutions Announce Transformative Combination

Waters Corporation and Becton, Dickinson and Company's Biosciences & Diagnostic Solutions business will combine to create a new life science and diagnostics leader focused on regulated, high-volume testing.

Summary

• Waters Corporation announced an agreement to combine with Augusta SpinCo Corporation, a wholly owned subsidiary of Becton, Dickinson and Company, which comprises BD's Biosciences & Diagnostic Solutions business.
• The proposed transaction aims to create a life science and diagnostics leader focused on regulated, high-volume testing.
• The combined company will offer a comprehensive product portfolio across liquid chromatography, mass spectrometry, flow cytometry, and diagnostic solutions.
• The combination is expected to accelerate innovation in bioseparations, biological characterization, and multiplex diagnostics.
• The transaction is anticipated to close around the end of the first quarter of calendar year 2026, subject to regulatory approvals, Waters shareholder approval, and other customary closing conditions.
• Until closing, Waters and BD's Biosciences & Diagnostic Solutions business will operate independently.

Sentiment

Score: 8

Explanation: The communication is overwhelmingly positive, highlighting strategic benefits, complementary strengths, and a 'big win' for stakeholders, despite acknowledging standard merger-related risks.

Positives

• The combination creates a life science and diagnostics leader focused on regulated, high-volume testing.
• BD's Biosciences & Diagnostic Solutions business's portfolio and expertise are highly complementary to Waters'.
• The new combined company will offer a comprehensive product portfolio across liquid chromatography, mass spectrometry, flow cytometry, and diagnostic solutions.
• Opportunities exist to accelerate innovation in bioseparations, biological characterization, and multiplex diagnostics.
• The transaction is expected to enable faster development of new scientific breakthroughs and customer solutions.
• The combination is described as a 'big win' for both Waters and BD's Biosciences & Diagnostic Solutions business, and for stakeholders, including customers.

Risks

• One or more closing conditions, including certain regulatory approvals, may not be satisfied or waived on a timely basis or at all, potentially due to governmental prohibition, delay, or refusal, or the imposition of conditions, limitations, or restrictions.
• The required approval by Waters stockholders may not be obtained.
• The proposed transaction may not be completed on the terms or in the time frame expected, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty exists regarding the expected financial performance of the combined company following completion of the proposed transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including synergies, may occur due to delays in completion or integration.
• The combined company may face difficulties in implementing its business strategy.
• Difficulties and delays may arise in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel is a risk.
• Any event could occur that gives rise to the termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations in connection with the proposed transaction may affect its timing or occurrence or result in significant costs.
• Evolving legal, regulatory, and tax regimes could impact the transaction.
• Changes in general economic and/or industry-specific conditions or volatility from tariffs could affect outcomes.
• Actions by third parties, including government agencies, pose a risk.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• Greater than expected difficulty may arise in separating SpinCo's business from other BD businesses.
• The pendency of the proposed transaction may disrupt management time from ongoing business operations.
• Other effects of the pendency of the proposed transaction on relationships with employees, customers, suppliers, or other counterparties are possible.

Future Outlook

The proposed transaction is expected to close around the end of the first quarter of calendar year 2026, subject to regulatory and shareholder approvals. The combined company aims to accelerate innovation, expand its product portfolio across key life science and diagnostics areas, and provide enhanced service to customers.

Management Comments

• "We are excited to share that we announced an agreement to combine BDs Biosciences & Diagnostic Solutions business with Waters to create a life science and diagnostics leader focused on regulated, high-volume testing."
• "Bringing our two businesses together through this transformative transaction will enable us to accelerate innovation on behalf of researchers, clinicians, and patients."
• "BDs portfolio and expertise are highly complementary to ours, and we are both driven by innovation and an unrelenting commitment to our customers."
• "The new combined company will be positioned to offer customers a comprehensive product portfolio across liquid chromatography, mass spectrometry, flow cytometry, and diagnostic solutions."
• "This is a big win for both Waters and BDs Biosciences & Diagnostic Solutions business, but more importantly, it is a win for our stakeholders, including you."

Industry Context

This proposed combination represents a significant consolidation and strategic expansion within the life science and diagnostics industry. By merging Waters' expertise in liquid chromatography and mass spectrometry with BD's strengths in flow cytometry and diagnostics, the new entity aims to create a more comprehensive offering, addressing a broader range of customer needs in regulated, high-volume testing. This move positions the combined company to compete more effectively by offering integrated solutions and accelerating innovation in key areas like bioseparations and multiplex diagnostics.

Legal Proceedings

• Risk of stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations that may affect timing, occurrence, or result in significant costs.

Stakeholder Impact

• Customers: Expected to benefit from a comprehensive product portfolio, accelerated innovation, new scientific breakthroughs, faster customer solutions, and better service.
• Shareholders: Waters shareholder approval is required for the transaction.
• Employees: Risk of inability to retain and hire key personnel; potential disruption to management time; effects on relationships with employees due to transaction pendency.
• Suppliers: Potential effects on relationships with suppliers due to transaction pendency.
• Other Counterparties: Potential effects on relationships with other counterparties due to transaction pendency.

Next Steps

• Receipt of required regulatory approvals.
• Waters shareholder approval.
• Satisfaction of other customary closing conditions.
• Filing of a registration statement on Form S-4 by Waters, including a preliminary and definitive proxy statement/prospectus.
• Filing of a registration statement on Form 10 by SpinCo, serving as an information statement/prospectus.
• Waters and BD's Biosciences & Diagnostic Solutions business will continue to operate independently until the transaction closes.

Key Dates

Keywords

Waters Corporation, Becton Dickinson, BD Biosciences & Diagnostic Solutions, Augusta SpinCo Corporation, Merger, Acquisition, Life Science, Diagnostics, Liquid Chromatography, Mass Spectrometry, Flow Cytometry, Bioseparations, Biological Characterization, Multiplex Diagnostics, SEC Filing, Corporate Combination